After finishing at $15.59 in the prior trading day, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) closed at $14.85, down -4.75%. In other words, the price has decreased by -$0.74 from its previous closing price. On the day, 627961 shares were traded. DCPH stock price reached its highest trading level at $15.72 during the session, while it also had its lowest trading level at $14.65.
Ratios:
Our goal is to gain a better understanding of DCPH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.59 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On October 30, 2023, Piper Sandler Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $23.
Stifel Upgraded its Hold to Buy on August 10, 2023, whereas the target price for the stock was revised from $14 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 ’24 when Kelly Thomas Patrick sold 3,010 shares for $15.62 per share. The transaction valued at 47,009 led to the insider holds 80,350 shares of the business.
Sherman Matthew L sold 2,615 shares of DCPH for $40,840 on Feb 16 ’24. The EVP & Chief Medical Officer now owns 108,739 shares after completing the transaction at $15.62 per share. On Feb 16 ’24, another insider, Pitman Jama, who serves as the SVP, Chief Development Officer of the company, sold 2,267 shares for $15.62 each. As a result, the insider received 35,405 and left with 68,031 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DCPH now has a Market Capitalization of 1.20B and an Enterprise Value of 920.76M. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.35 while its Price-to-Book (P/B) ratio in mrq is 3.41. Its current Enterprise Value per Revenue stands at 5.64 whereas that against EBITDA is -4.41.
Stock Price History:
Over the past 52 weeks, DCPH has reached a high of $17.73, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 15.36, while the 200-Day Moving Average is calculated to be 13.94.
Shares Statistics:
The stock has traded on average 536.23K shares per day over the past 3-months and 570.05k shares per day over the last 10 days, according to various share statistics. A total of 80.50M shares are outstanding, with a floating share count of 49.41M. Insiders hold about 38.85% of the company’s shares, while institutions hold 63.77% stake in the company. Shares short for DCPH as of Feb 29, 2024 were 5.51M with a Short Ratio of 10.27, compared to 5.34M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.82% and a Short% of Float of 9.08%.
Earnings Estimates
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.63, while EPS last year was -$0.6. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.49 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.96 and -$2.59 for the fiscal current year, implying an average EPS of -$2.2. EPS for the following year is -$1.67, with 10 analysts recommending between -$0.53 and -$2.39.
Revenue Estimates
9 analysts predict $46.08M in revenue for the current quarter. It ranges from a high estimate of $48.9M to a low estimate of $42M. As of the current estimate, Deciphera Pharmaceuticals Inc’s year-ago sales were $33.45M, an estimated increase of 37.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $48.8M, an increase of 27.40% less than the figure of $37.80% in the same quarter last year. There is a high estimate of $51.1M for the next quarter, whereas the lowest estimate is $44.1M.
A total of 9 analysts have provided revenue estimates for DCPH’s current fiscal year. The highest revenue estimate was $207.4M, while the lowest revenue estimate was $186.7M, resulting in an average revenue estimate of $199.84M. In the same quarter a year ago, actual revenue was $163.36M, up 22.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $258.88M in the next fiscal year. The high estimate is $397M and the low estimate is $215.9M. The average revenue growth estimate for next year is up 29.50% from the average revenue estimate for this year.
